Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.

Capelletti M, Dodge ME, Ercan D, Hammerman PS, Park SI, Kim J, Sasaki H, Jablons DM, Lipson D, Young L, Stephens PJ, Miller VA, Lindeman NI, Munir KJ, Richards WG, Jänne PA.

Clin Cancer Res. 2014 Dec 15;20(24):6551-8. doi: 10.1158/1078-0432.CCR-14-1337. Epub 2014 Oct 7.

2.

Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients.

Ou SI, Horn L, Cruz M, Vafai D, Lovly CM, Spradlin A, Williamson MJ, Dagogo-Jack I, Johnson A, Miller VA, Gadgeel S, Ali SM, Schrock AB.

Lung Cancer. 2017 Sep;111:61-64. doi: 10.1016/j.lungcan.2017.07.006. Epub 2017 Jul 11.

3.

FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.

Wang R, Wang L, Li Y, Hu H, Shen L, Shen X, Pan Y, Ye T, Zhang Y, Luo X, Zhang Y, Pan B, Li B, Li H, Zhang J, Pao W, Ji H, Sun Y, Chen H.

Clin Cancer Res. 2014 Aug 1;20(15):4107-14. doi: 10.1158/1078-0432.CCR-14-0284. Epub 2014 May 21.

4.

FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium.

Best SA, Harapas CR, Kersbergen A, Rathi V, Asselin-Labat ML, Sutherland KD.

Oncogene. 2018 Nov;37(46):6096-6104. doi: 10.1038/s41388-018-0399-5. Epub 2018 Jul 10.

5.

Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.

Di Stefano AL, Fucci A, Frattini V, Labussiere M, Mokhtari K, Zoppoli P, Marie Y, Bruno A, Boisselier B, Giry M, Savatovsky J, Touat M, Belaid H, Kamoun A, Idbaih A, Houillier C, Luo FR, Soria JC, Tabernero J, Eoli M, Paterra R, Yip S, Petrecca K, Chan JA, Finocchiaro G, Lasorella A, Sanson M, Iavarone A.

Clin Cancer Res. 2015 Jul 15;21(14):3307-17. doi: 10.1158/1078-0432.CCR-14-2199. Epub 2015 Jan 21.

6.

FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling.

Daly C, Castanaro C, Zhang W, Zhang Q, Wei Y, Ni M, Young TM, Zhang L, Burova E, Thurston G.

Oncogene. 2017 Jan 26;36(4):471-481. doi: 10.1038/onc.2016.216. Epub 2016 Jun 27.

7.

Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma.

Yuan L, Liu ZH, Lin ZR, Xu LH, Zhong Q, Zeng MS.

Cancer Biol Ther. 2014;15(12):1613-21. doi: 10.4161/15384047.2014.961874.

8.

Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR-mutated Lung Adenocarcinoma Reveals an Acquired FGFR3-TACC3 Fusion.

Allen JM, Schrock AB, Erlich RL, Miller VA, Stephens PJ, Ross JS, Ou SI, Ali SM, Vafai D.

Clin Lung Cancer. 2017 May;18(3):e219-e222. doi: 10.1016/j.cllc.2016.12.006. Epub 2016 Dec 22. No abstract available.

9.

Drug-sensitive FGFR3 mutations in lung adenocarcinoma.

Chandrani P, Prabhash K, Prasad R, Sethunath V, Ranjan M, Iyer P, Aich J, Dhamne H, Iyer DN, Upadhyay P, Mohanty B, Chandna P, Kumar R, Joshi A, Noronha V, Patil V, Ramaswamy A, Karpe A, Thorat R, Chaudhari P, Ingle A, Choughule A, Dutt A.

Ann Oncol. 2017 Mar 1;28(3):597-603. doi: 10.1093/annonc/mdw636.

10.

Oncogenic Gene Fusion FGFR3-TACC3 Is Regulated by Tyrosine Phosphorylation.

Nelson KN, Meyer AN, Siari A, Campos AR, Motamedchaboki K, Donoghue DJ.

Mol Cancer Res. 2016 May;14(5):458-69. doi: 10.1158/1541-7786.MCR-15-0497. Epub 2016 Feb 11.

11.

Transforming fusions of FGFR and TACC genes in human glioblastoma.

Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, Liu EM, Reichel J, Porrati P, Pellegatta S, Qiu K, Gao Z, Ceccarelli M, Riccardi R, Brat DJ, Guha A, Aldape K, Golfinos JG, Zagzag D, Mikkelsen T, Finocchiaro G, Lasorella A, Rabadan R, Iavarone A.

Science. 2012 Sep 7;337(6099):1231-5. doi: 10.1126/science.1220834. Epub 2012 Jul 26.

12.

FGFR3-TACC3 fusion in solid tumors: mini review.

Costa R, Carneiro BA, Taxter T, Tavora FA, Kalyan A, Pai SA, Chae YK, Giles FJ.

Oncotarget. 2016 Aug 23;7(34):55924-55938. doi: 10.18632/oncotarget.10482. Review.

13.

Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples.

Kurobe M, Kojima T, Nishimura K, Kandori S, Kawahara T, Yoshino T, Ueno S, Iizumi Y, Mitsuzuka K, Arai Y, Tsuruta H, Habuchi T, Kobayashi T, Matsui Y, Ogawa O, Sugimoto M, Kakehi Y, Nagumo Y, Tsutsumi M, Oikawa T, Kikuchi K, Nishiyama H.

PLoS One. 2016 Dec 8;11(12):e0165109. doi: 10.1371/journal.pone.0165109. eCollection 2016.

14.

Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing.

Majewski IJ, Mittempergher L, Davidson NM, Bosma A, Willems SM, Horlings HM, de Rink I, Greger L, Hooijer GK, Peters D, Nederlof PM, Hofland I, de Jong J, Wesseling J, Kluin RJ, Brugman W, Kerkhoven R, Nieboer F, Roepman P, Broeks A, Muley TR, Jassem J, Niklinski J, van Zandwijk N, Brazma A, Oshlack A, van den Heuvel M, Bernards R.

J Pathol. 2013 Jul;230(3):270-6. doi: 10.1002/path.4209.

PMID:
23661334
15.

Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.

Han JY, Kim SH, Lee YS, Lee SY, Hwang JA, Kim JY, Yoon SJ, Lee GK.

Lung Cancer. 2014 Aug;85(2):161-7. doi: 10.1016/j.lungcan.2014.04.009. Epub 2014 Apr 29.

PMID:
24857785
17.

Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.

Cheung HW, Du J, Boehm JS, He F, Weir BA, Wang X, Butaney M, Sequist LV, Luo B, Engelman JA, Root DE, Meyerson M, Golub TR, Jänne PA, Hahn WC.

Cancer Discov. 2011 Dec;1(7):608-25. doi: 10.1158/2159-8290.CD-11-0046. Epub 2011 Oct 17.

18.

Oncogenic FGFR3 gene fusions in bladder cancer.

Williams SV, Hurst CD, Knowles MA.

Hum Mol Genet. 2013 Feb 15;22(4):795-803. doi: 10.1093/hmg/dds486. Epub 2012 Nov 21.

19.

Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1.

Nakanishi Y, Akiyama N, Tsukaguchi T, Fujii T, Satoh Y, Ishii N, Aoki M.

Mol Cancer Ther. 2015 Mar;14(3):704-12. doi: 10.1158/1535-7163.MCT-14-0927-T. Epub 2015 Jan 14.

20.

A metabolic function of FGFR3-TACC3 gene fusions in cancer.

Frattini V, Pagnotta SM, Tala, Fan JJ, Russo MV, Lee SB, Garofano L, Zhang J, Shi P, Lewis G, Sanson H, Frederick V, Castano AM, Cerulo L, Rolland DCM, Mall R, Mokhtari K, Elenitoba-Johnson KSJ, Sanson M, Huang X, Ceccarelli M, Lasorella A, Iavarone A.

Nature. 2018 Jan 11;553(7687):222-227. doi: 10.1038/nature25171. Epub 2018 Jan 3.

Supplemental Content

Support Center